Corporate$AZN2:06 AM ET

AstraZeneca: other phase III volrustomig trials remain on track

By BORSA NewsroomPublished Aug 17, 2026, 2:06 AM EDTUpdated Aug 23, 2026, 6:18 AM EDT

AstraZeneca confirmed that its other phase III trials for volrustomig are proceeding as planned. No further details were disclosed.

Sentimentneutral 50

Neutral · 50 of 100

Impact20

low · stays off the top drivers

Confidence55%

developing read · single wire

Eventdeveloping

v1 · alerted to followers

WHAT WE KNOW

AstraZeneca made a statement about volrustomig phase III trials.
The statement says other trials remain on track.
AstraZeneca issued a statement indicating that its other phase III trials for volrustomig remain on track. The statement did not specify which trials or provide any data.